Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
23/12/2025 14:01
Dec 23 (Reuters) - Phio Pharmaceuticals Corp PHIO.O: PHIO PHARMACEUTICALS CORP - TO BEGIN TOXICOLOGY STUDY FOR PH-762 BEFORE HUMAN TRIALS - SEC FILING PHIO PHARMACEUTICALS CORP - NO DOSE-LIMITING TOXICITIES IN PH-762 TRIAL - SEC FILING PHIO PHARMACEUTICALS CORP - INITIATIVES CONTINUING TO ADVANCE DELIVERY OF COMMERCIALLY VIABLE DRUG PRODUCT IN 2026 PHIO PHARMACEUTICALS CORP - PH-762 HAS BEEN WELL TOLERATED IN ALL ENROLLED PATIENTS IN EACH ESCALATING DOSE COHORT Source text: [ID:n0001437749-25-038607] Further company coverage: PHIO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing